Natco Pharma Ltd Share Price
As on 21 November 2025 at 05:19 IST
Natco Pharma Q1 FY26 Results:
Net profit for the period declined 28% to ₹481 crores in Q1 FY26, from ₹669 crores in Q1 FY25. Total income for the quarter decreased over 1% year-on-year to ₹1,391 crores from ₹1,411 crores.
About Natco Pharma Ltd
Natco Pharma Ltd, founded in the year 1981, is a vertically integrated pharmaceutical company. It specialises in finished dosage formulations and active pharmaceutical ingredients. Headquartered in Hyderabad, Telangana, the company has carved a niche in complex products and therapeutic areas, particularly oncology. From modest beginnings, Natco has become a key player in the pharmaceutical industry, serving domestic and international markets. Beyond pharmaceuticals, the company has diversified into agrochemicals, offering crop health sciences products. It is not the top stock in the pharmaceutical sector. However, Natco Pharma maintains a robust market position. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-0.42%
Over 6 Months
-4.16%
Over 1 Year
-39.17%
Over 3 Years
45.77%
Natco Pharma Ltd Summary
Close ₹830.15
Open ₹818
High ₹848
Low ₹811.40
Volume 23,13,933
Net Turnover (in Cr) ₹193.56
52Wk High ₹1,505
52Wk Low ₹726.80
52Wk High / Low
726.80
1,505
Natco Pharma Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹14,868.81
EPS (TTM) 84.75
Book Value (BV) 461.80
Div. Yield 0.72 %
P/E (TTM) 9.79
Price/Book Value 1.80
Delivery % 23.12 %
Face Value 2
Key Ratios
PE Ratio 7.72
PB Ratio 1.95
EV to Sales 3.10
PEG Ratio 0.19
ROA 24.10
ROE 28.63
Debt-Equity 0.05
Net Profit Margin 45.19
Operating Profit Margin 60.22
Natco Pharma Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 4,784 | 4,126.90 | 2,811.70 | 2,043.80 | 2,155.70 |
| Total Expenses | 2,492.60 | 2,453.40 | 1,949.80 | 1,841.60 | 1,576.10 |
| Profit Before Tax | 2,291.40 | 1,673.50 | 861.90 | 202.20 | 579.60 |
| Profit After Tax | 1,883.40 | 1,388.30 | 715.30 | 170 | 442.40 |
| Operating Profit After Depreciation | 2,315.30 | 1,692.70 | 876.40 | 219.90 | 592.90 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 2,698 | 2,490.80 | 2,426.90 | 2,311.80 | 2,023.20 |
| Total Non Current Assets | 3,360.80 | 2,882.80 | 2,657.10 | 2,622.40 | 2,447.10 |
| Total Current Assets | 5,270 | 4,023.50 | 3,000.30 | 2,486.70 | 2,344.80 |
| Total Assets | 8,630.80 | 6,906.30 | 5,657.40 | 5,109.10 | 4,791.90 |
| Total Shareholder's Fund | 7,607 | 5,853.10 | 4,873.80 | 4,263.60 | 4,121.60 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 1,696.80 | 1,211.60 | 849.10 | 46.50 | 298.80 |
| Net Cash Used In Investing Activities | -1,436.50 | -1,026.20 | -465.30 | 4 | -107.10 |
| Net Cash Used In Financing Activities | -210.70 | -246.90 | -363 | 34.80 | -185.70 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 4,415.80 | 3,673.60 | 2,436.50 | 1,862.40 | 1,754.60 |
| Total Expenses | 2,189.80 | 2,118.30 | 1,665.80 | 1,706.50 | 1,362.40 |
| Profit Before Tax | 2,226 | 1,555.30 | 770.70 | 155.90 | 392.20 |
| Profit After Tax | 1,850.40 | 1,306.60 | 637.10 | 139.10 | 309.50 |
| Operating Profit After Depreciation | 2,245.60 | 1,569.80 | 779.30 | 169.20 | 403.50 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 2,516.80 | 2,286.70 | 2,233.80 | 2,174.20 | 2,005.90 |
| Total Non Current Assets | 3,581.90 | 3,143.60 | 2,893.20 | 2,810.30 | 2,584 |
| Total Current Assets | 4,688 | 3,410.40 | 2,494.70 | 2,167.70 | 2,168.50 |
| Total Assets | 8,269.90 | 6,554 | 5,387.90 | 4,978 | 4,752.50 |
| Total Shareholder's Fund | 7,333.90 | 5,592.30 | 4,702 | 4,191.90 | 4,091.10 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 1,662 | 1,196.40 | 784.40 | 57.70 | 183.50 |
| Net Cash Used In Investing Activities | -1,443.90 | -960.50 | -436.60 | -92.50 | -3.20 |
| Net Cash Used In Financing Activities | -212.40 | -237.30 | -346.80 | 35.60 | -183.10 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 1,363 | 1,328.90 | 1,221 | 474.80 | 1,371.10 |
| Total Expenses | 783.80 | 757.90 | 672.90 | 436 | 566.80 |
| Profit Before Tax | 613.70 | 571.90 | 505.90 | 163.70 | 818.20 |
| Profit After Tax | 517.90 | 480.30 | 406 | 132.40 | 676.50 |
| Operating Profit after Depreciation | 679.20 | 632.70 | 614.40 | 215.10 | 868.10 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 1,264.30 | 1,192.70 | 1,157.40 | 407.60 | 1,292.60 |
| Total Expenses | 711.80 | 653 | 596.20 | 378.20 | 501.90 |
| Profit Before Tax | 586 | 542.90 | 520.80 | 150.30 | 796.90 |
| Profit After Tax | 500.90 | 464.10 | 428.10 | 124.90 | 661.10 |
| Operating Profit after Depreciation | 645.80 | 599.30 | 623.30 | 197.40 | 842.10 |
Natco Pharma Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 811.70
S2 793.25
S3 775.10
Pivot 829.85
R1 848.30
R2 866.45
R3 884.90
Moving Average
20 SMA 820.34
50 SMA 829.64
100 SMA 881.88
200 SMA 884.71
Natco Pharma Ltd Corporate Actions
Natco Pharma Ltd
₹1.5/Share
Announcement Date 20 Nov 2025
Record Date 20 Nov 2025
Div Yield 75%
Natco Pharma Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,784.15 | ₹4,28,077.35 |
| Divis Laboratories Ltd | ₹6,453.65 | ₹1,71,324.13 |
| Torrent Pharmaceuticals Ltd | ₹3,729.85 | ₹1,26,229.40 |
| Cipla Ltd | ₹1,526.35 | ₹1,23,294.16 |
| Dr Reddys Laboratories Ltd | ₹1,250.10 | ₹1,04,335.99 |
Natco Pharma Ltd Top Mutal Funds Invested
Natco Pharma Ltd News
Board of Natco Pharma recommends interim dividend
Of Rs 1.5 per share
14 Nov 2025, 04:01 pm
Natco Pharma to conduct board meeting
On 14 November 2025
10 Nov 2025, 02:53 pm
Natco Pharma launches Everolimus tablets 1mg
31 Oct 2025, 09:23 am
Natco Pharma Ltd eases for fifth straight session
Natco Pharma Ltd is quoting at Rs 852.8, down 0.16% on the day as on 13:19 IST on the NSE. The stock jumped 1.26% in last one year as compared to a 4.64% slide in NIFTY and a 5.1% spurt in the Nifty Pharma index.
25 Sep 2025, 01:35 pm
Board of Natco Pharma considers demerger of agro biz
At meeting held on 25 September 2025
25 Sep 2025, 11:25 am
Natco Pharma Ltd Stock Analysis
- Annual revenue for Natco Pharma Ltd increased by 20.20% to ₹4,415.80 crore in FY 2025 from ₹3,673.60 crore in FY 2024.
- Annual Net Profit for Natco Pharma Ltd increased by 41.62% to ₹1,850.40 crore in FY 2025 from ₹1,306.60 crore in FY 2024.
- Promoter Shareholding in Natco Pharma Ltd decreased by 0.16% in the most recent quarter, from 49.56% in June 2025 to 49.48% in September 2025.
- Natco Pharma Ltd delivered a 1-year return of -39.17% compared to the Nifty 50, which provided a return of 10.78% as of the last trading session.
- Natco Pharma Ltd share price moved up by 3.23% from its previous close of INR ₹830.15. The latest Natco Pharma Ltd share price is INR ₹857.
- Natco Pharma Ltd share price today has been at a low of 828.30 and a high of 864.40. Over the past 52 weeks, the Natco Pharma Ltd share price has seen a low of 726.80 and a high of 1,505.
About Natco Pharma Ltd
Natco Pharma Ltd, founded in 1981, is a vertically integrated pharmaceutical company. It specialises in finished dosage formulations and active pharmaceutical ingredients. Headquartered in Hyderabad, Telangana, the company has carved a niche in complex products and therapeutic areas, particularly oncology. From modest beginnings, Natco has become a key player in the pharmaceutical industry, serving domestic and international markets. Beyond pharmaceuticals, the company has diversified into agrochemicals, offering crop health sciences products. Its expertise lies in developing and marketing specialised medicines, contributing significantly to healthcare accessibility.
Over decades, Natco Pharma has consistently expanded its operations, solidifying its position as a crucial contributor to the pharmaceutical sector. As a result, it has established a reputation for innovation and quality. The company has a team of professional managerial promoters who are
Natco Pharma Ltd. has profoundly impacted the pharmaceutical industry through its affordability, innovation, and quality commitment. The company’s efforts in developing generic medications, particularly in oncology, have made life-saving treatments accessible to many patients. Its ongoing dedication to improving healthcare outcomes ensures it will remain a vital player in its industry. This makes a positive difference in the lives of patients worldwide.
Over decades, Natco Pharma has consistently expanded its operations, solidifying its position as a crucial contributor to the pharmaceutical sector. As a result, it has established a reputation for innovation and quality. The company has a team of professional managerial promoters who are
- G S Murthy
- V C Nannapaneni
- Rajeev Nannapaneni
- T V Rao
- D G Prasad
Impact of Natco Pharma Limited
Natco Pharma Ltd. has significantly impacted the pharmaceutical industry in India and globally. The company’s contributions span various aspects. It includes developing affordable medicines and efforts to improve public health. This impact results from Natco Pharma’s commitment to innovation and accessibility. One of the most notable impacts of Natco Pharma is its role in making life-saving medications more affordable. The company has been at the forefront of producing generic versions of high-cost drugs. This is especially notable in the oncology segment. It has allowed patients to access important treatments at a fraction of the cost of branded medications. The availability of affordable generics has improved the quality of life for many patients. Natco Pharma’s focus on oncology has been particularly impactful. The company has developed and launched several generic cancer drugs. These drugs have provided cost-effective alternatives to expensive branded medications. It also helps to contribute to the overall improvement in cancer care. The company’s efforts in this area have been recognised globally. Natco Pharma continues to be a key player in the oncology pharmaceutical market. Natco Pharma’s impact extends beyond just providing medications. The company has invested in research and development to innovate and improve drug formulations. This focus on R&D has led to the development of new and improved medications that offer better efficiency and safety profiles. The company’s dedication to innovation ensures that it remains at the cutting edge of pharmaceutical advancements, continually bringing new solutions to the market. The company’s efforts in the agrochemical sector also highlight its broader impact. Its crop health sciences division develops products that help improve agricultural productivity. These agrochemical products support farmers in protecting their crops from pests and diseases. As a result, Natco Pharma's products contribute to food security and agricultural sustainability. This diversification into agrochemicals demonstrates its commitment to addressing various societal needs through its expertise in chemical formulations. Natco Pharma’s impact is also evident in its corporate social responsibility initiatives. The company actively engages in programs to improve education and community development. These initiatives are designed to uplift underprivileged communities and provide better opportunities and resources. Through its CSR efforts, Natco Pharma has made a positive difference in the lives of many individuals. This helps it to reinforce its role as a responsible corporate citizen. The company’s global presence further amplifies its impact. Natco Pharma exports its products to numerous countries. Doing this ensures patients worldwide can access affordable and effective medications. This reach has positioned Natco Pharma as a significant player in the pharmaceutical industry, helping it to contribute to improved healthcare outcomes globally.Natco Pharma Ltd. has profoundly impacted the pharmaceutical industry through its affordability, innovation, and quality commitment. The company’s efforts in developing generic medications, particularly in oncology, have made life-saving treatments accessible to many patients. Its ongoing dedication to improving healthcare outcomes ensures it will remain a vital player in its industry. This makes a positive difference in the lives of patients worldwide.
FAQ’s
What is the share price of Natco Pharma Ltd today?
Natco Pharma Ltd share price as on 20 Nov 2025 is ₹ 857.0
What is the Market Cap of Natco Pharma Ltd?
The market cap of Natco Pharma Ltd stock is ₹14,868.81 Cr.
What is the PE Ratio of Natco Pharma Ltd?
The Price to Earnings (P/E) Ratio of Natco Pharma Ltd is 7.72
What is the PB Ratio of Natco Pharma Ltd?
The Price to Book (P/B) Ratio of Natco Pharma Ltd is 1.95
What is the 52 week high of Natco Pharma Ltd Share Price?
The 52 week high of Natco Pharma Ltd share price stands at ₹1,505
What is the 52 week low of Natco Pharma Ltd Share Price?
The 52 week low of Natco Pharma Ltd share price stands at ₹726.80
How can I buy shares of Natco Pharma Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Natco Pharma Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
